Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691498 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL1236129 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL8222457 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL19261937 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL12103325 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL1104912 | 0.89 | KLK5 (0.61) | KLK5CTSSPSEN1PSEN2APH1B | |
| SCHEMBL13538226 | 0.87 | KLK5 (0.48) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5945619 | 0.87 | KLK5 (0.46) | KLK5CTSSCTSKPSEN1PSEN2 | |
| SCHEMBL5945448 | 0.85 | REN (0.54) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13630987 | 0.85 | REN (0.54) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | KLK5 380/4885CTSS 53/4885CTSK 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.